1032350-05-2 Usage
Description
1-(4-bromophenyl)cyclobutane-1-carboxamide is a chemical compound with the molecular formula C11H12BrNO. It is a cyclobutane derivative that contains a bromophenyl group and a carboxamide functional group. 1-(4-bromophenyl)cyclobutane-1-carboxamide is typically used in pharmaceutical research and drug development, where it may be investigated for its potential therapeutic properties. As a cyclobutane derivative, it may exhibit unique structural and chemical properties that could make it useful in various applications. However, further research and testing would be necessary to fully understand its potential uses and properties.
Uses
Used in Pharmaceutical Research and Drug Development:
1-(4-bromophenyl)cyclobutane-1-carboxamide is used as a research compound for investigating its potential therapeutic properties. Its unique structural and chemical properties as a cyclobutane derivative may contribute to its usefulness in this application.
Used in Chemical Synthesis:
1-(4-bromophenyl)cyclobutane-1-carboxamide may be used as a starting material or intermediate in the synthesis of other chemical compounds, particularly those with pharmaceutical or medicinal applications.
Used in Material Science:
Due to its unique structural and chemical properties, 1-(4-bromophenyl)cyclobutane-1-carboxamide may have potential applications in material science, such as in the development of new materials with specific properties or functions.
Note: The specific applications and industries for 1-(4-bromophenyl)cyclobutane-1-carboxamide are not provided in the materials. The uses listed above are based on the general information provided and the typical applications of cyclobutane derivatives in various fields. Further research and testing would be necessary to confirm the specific uses and industries for this compound.
Check Digit Verification of cas no
The CAS Registry Mumber 1032350-05-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,2,3,5 and 0 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1032350-05:
(9*1)+(8*0)+(7*3)+(6*2)+(5*3)+(4*5)+(3*0)+(2*0)+(1*5)=82
82 % 10 = 2
So 1032350-05-2 is a valid CAS Registry Number.
1032350-05-2Relevant articles and documents
Oxadiazole Amine Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same
-
, (2017/07/18)
The present invention relates to a novel compound having an activity of inhibiting histone deacetylase 6 (HDAC6), an optical isomer thereof or a pharmaceutically acceptable salt thereof, a use thereof for preparation of a drug for treatment, a pharmaceutical composition comprising the same, a treatment method using the composition, and a method for preparing the same. The novel compound, an optical isomer thereof or a pharmaceutically acceptable salt thereof according to the present invention has an activity of inhibiting histone deacetylase 6 (HDAC6), and is effective for preventing or treating HDAC6-related diseases, including infectious diseases; neoplasm; endocrine, nutritional and metabolic diseases; mental and behavior disorders; nerve disorders; eye and adnexa diseases; cardiovascular diseases; respiratory diseases; digestive organ diseases; skin and subcutaneous tissue diseases; musculoskeletal and connective tissue diseases; or congenital malformation, deformation and chromosomal abnormality.COPYRIGHT KIPO 2017
IL-23 ANTAGONISTS FOR TREATMENT OR PREVENTION OF SKIN RASH ASSOCIATED WITH TREATMENT WITH P13K/AKT PATHWAY INHIBITORS
-
, (2013/03/26)
The present invention provides methods for use of interleukin-23 (IL-23) antagonists to treat or prevent skin rash associated with treatment with PI3K/AKT pathway inhibitors, such as treatment of cancer.
Inhibitors of Akt activity
-
Page/Page column 59, (2008/12/06)
The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.
